Impact of baseline HIV-1 tropism on viral response and CD4 cell count gains in HIV-infected patients receiving first-line antiretroviral therapy

Journal of Infectious Diseases

Volumn 204, Issue 1, 2011, Pages 139-144

  Seclén, Eduardo ^a   Soriano, Vicente ^a   González, María M ^a   Martín Carbonero, Luz ^a   Gellermann, Holger ^b   Distel, Manuel ^b   Kadus, Werner ^b   Poveda, Eva ^a  

^a HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^b BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; ATAZANAVIR PLUS RITONAVIR; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; NEVIRAPINE; VIRUS RNA;

ANTIVIRAL THERAPY; ARTICLE; BLOOD ANALYSIS; CD4 LYMPHOCYTE COUNT; CLADISTICS; CONTROLLED STUDY; FEMALE; GENE DOSAGE; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; MAJOR CLINICAL STUDY; MALE; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SEROTYPE; TREATMENT OUTCOME; UNINDEXED SEQUENCE; VIRAL TROPISM; VIRUS LOAD; VIRUS STRAIN;

ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; CD4-POSITIVE T-LYMPHOCYTES; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; MALE; PLASMA; TREATMENT OUTCOME; VIRAL TROPISM;

EID: 79957938150     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1093/infdis/jir218     Document Type: Article

References (17)

1. Poveda E, Briz V, Quiñones-Mateu M, Soriano V. HIV tropism: diagnostic tools and implications for diseases progression and treatment with entry inhibitors. AIDS 2006; 20:1359-67. (Pubitemid 43948242)
2. Daar E, Kesler K, Petropoulos C, et al. Baseline HIV type 1 coreceptor tropism predicts disease progression. Clin Infect Dis 2007; 45:643-9. (Pubitemid 47328648)
3. Goetz M, Leduc R, Kostman J, et al. Relationship between HIV coreceptor tropism and disease progression in persons with untreated chronic HIV infection. J Acquir Immune Defic Syndr 2009; 50:259-66.
4. Waters L, Mandalia S, Randell P, Wildfire A, Gazzard B, Moyle G. The impact of HIV tropism on decreases in CD4 cell count, clinical progression, and subsequent response to a first antiretroviral therapy regimen. Clin Infect Dis 2008; 46:1617-23. (Pubitemid 351706746)
5. Schuitemaker H, Koot M, Kootstra N, et al. Biological phenotype of HIV type 1 clones at different stages of infection: progression of disease is associated with a shift from mono-cytotropic to T-cell-tropic virus population. J Virol 1992; 66:1354-60.
6. Hunt P, Harrigan R, Huang W, et al. Prevalence of CXCR4 tropism among antiretroviral-treated HIV-1 infected patients with detectable viremia. J Infect Dis 2006; 194:926-30. (Pubitemid 44454078)
7. Briz V, Poveda E, González MM, Martín-Carbonero L, González- González R, Soriano V. Impact of antiretroviral therapy on viral tropism in HIV-infected patients followed longitudinally for over 5 years. J Antimicrob Chemother 2008; 61:405-10.
8. Weiser B, Philpott S, Klimkait T, et al. HIV-1 coreceptor usage and CXCR4-specific viral load predict clinical disease progression during combination antiretroviral therapy. AIDS 2008; 22:469-79. (Pubitemid 351317288)
9. Brumme Z, Dong W, Yip B, et al. Clinical and immunological impact of HIV envelope V3 sequence variation after starting initial triple antiretroviral therapy. AIDS 2004; 18:F1-9.
10. Soriano V, Arastéh K, Migrone H, et al. Nevirapine versus atazanavir/ ritonavir, each combined with tenofovir/emtricitabine, in anti-retroviral- naïve HIV-1 patients: week 48 ArTEN results. Antivir Ther. [In press].
11. Poveda E, Seclén E, González MM, et al. Design and validation of new genotypic tools for easy and reliable estimation of HIV tropism before using CCR5 antagonists. J Antimicrob Chemother 2009; 63: 1006-10.
12. McGovern R, Dong W, Zhong X, et al. Population-based sequencing of the V3-loop is comparable to the enhanced sensitivity Trofile assay in predicting virologic response to maraviroc of treatment-naïve patients in the MERIT trial [abstract 92]. In: Program and abstracts of 17th Conference on Retroviruses and Opportunistic Infections. San Francisco, CA, 2010; 100.
13. Poveda E, Alcamí J, Paredes R, et al. Genotypic determination of HIV tropism - clinical and methodological recommendations to guide the therapeutic use of CCR5 antagonists. AIDS Rev 2010; 12:135-48.
14. Seclén E, Garrido C, González MM, et al. High sensitivity of specific genotypic tools for detection of X4 variants in antiretroviral- experienced patients suitable to be treated with CCR5 antagonists. J Antimicrob Chemother 2010; 65:1486-92.
15. Raymond S, Delobel P, Mavigner M, et al. Genotypic prediction of human immunodeficiency virus type 1 CRF02-AG tropism. J Clin Microbiol 2009; 47:2292-4.
16. Swenson L, Knapp D, Harrigan PR. Calibration and accuracy of the geno2pheno co-receptor algorithm for predicting HIV tropism for single and triplicate measurements of V3 genotype [abstract O122]. In: Program and abstracts of the 10th International Congress on Drug Therapy in HIV Infection. Glasgow, UK, 2010; 4.
17. McGovern RA, Thielen A, Mo T, et al. Population-based V3 geno-typic tropism assay: a retrospective analysis using screening samples from the A4001029 and MOTIVATE studies. AIDS 2010; 24:2517-25.